Tumor p53 status and response to topoisomerase II inhibitors

Drug Resistance Updates

Volumn 6, Issue 1, 2003, Pages 27-39

  Valkov, Nikola I ^a   Sullivan, Daniel M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Anticancer drugs; Apoptosis; Drug resistance; p53; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; HISTONE DEACETYLASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CHROMATIN STRUCTURE; DNA DAMAGE; DNA STRUCTURE; DRUG RESISTANCE; DRUG SENSITIVITY; HEMATOLOGIC MALIGNANCY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

EID: 0037303999     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00143-7     Document Type: Review

References (154)

1. Akyüz, N., Boehden, G.S., Süsse, S., Rimek, A., Preuss, U., Scheidtmann, K.-H., Wiesmüller, L., 2002. DNA substrate dependence of p-53-mediated regulation of double-strand break repair. Mol. Cell Biol. 22, 6306-6317.
2. Amundson, S.A., Patterson, A., Do, K.T., Fornace, Jr., A.J., 2002. A nucleotide excision repair master-switch: p53 regulated coordinate induction of global genomic repair genes. Cancer Biol. Ther. 1, 145-149.
3. Ao, Y., Rohde, L.H., Naumovski, L., 2001. p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. Oncogene 20, 2720-2725.
4. Arriola, E.L., Lopez, A.R., Chresta, C.M., 1999. Differential regulation of p21 waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 18, 1081-1091.
5. Bakhanashvili, M., 2001. Exonucleolytic proofreading by p53 protein. Eur. J. Biochem. 268, 2047-2054.
6. Baltaci, S., Orhan, D., Turkolmez, K., Yesilli, C., Beduk, Y., Tulunay, O., 2001. p53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. BJU Int. 87, 661-666.
7. Baptiste, N., Friedlander, P., Chen, X., Prives, C., 2002. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21, 9-21.
8. Bassi, L., Carloni, M., Fonti, E., Palma de la Peña, N., Meschini, R., Palitti, F., 2002. Pifithrin-α, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP-16) in human lymphoblastoid cells treated in vitro. Mutat. Res. 499, 163-176.
9. Beck, W.T., Morgan, S.E., Mo, Y.-Y., Bhat, U.G., 1999. Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. Drug Resist. Updates 2, 382-389.
10. Bernal, J.A., Luna, R., Espina, Á., Lázaro, I., Ramos-Morales, F., Romero, F., Arias, C., Silva, A., Tortolero, M., Pintor-Toro, J.A., 2002. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet. 32, 306-311.
11. Bjergbaek, L., Jensen, S., Westergaard, O., Andersen, A.H., 1999. Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase II alpha. J. Biol. Chem. 274, 26529-26536.
12. Bode, J., Kohwi, Y., Dickinson, L.A., Joh, T., Klehr, D., Mielke, C., Kohwi-Shigematsu, T., 1992. Biological significance of unwinding capability of nuclear matrix-associated DNAs. Science 255, 195-197.
13. Borst, P., Borst, J., Smets, L.A., 2001. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist. Updates 4, 129-137.
14. Bourdon, J.-C., Renzing, J., Robertson, P.L., Fernandes, K.N., Lane, D.P., 2002. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J. Cell Biol. 158, 235-246.
15. Bronner, C., Hopfner, R., Mousli, M., 2002. Transcriptional regulation of the human topoisomerase II alpha gene. Anticancer Res. 22, 605-612.
16. Brown, J.M., Wouters, B.G., 1999. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391-1399.
17. Brown, J.M., Wouters, B.G., 2001. Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist. Updates 4, 135-136.
18. Broxterman, H.J., Georgopapadakou, N., 2001. Cancer research 2001: drug resistance, new targets and drug combinations. Drug Resist. Updates 4, 197-209.
19. Buchop, S., Gibson, M.K., Wang, X.W., Wagner, P., Sturzbecher, H.W., Harris, C.C., 1997. Interaction of p53 with the human RAD51 protein. Nucleic Acids Res. 25, 3868-3874.
20. Burden, D.A., Sullivan, D.M., 1994. Phosphorylation of the α- and β-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry 33, 14651-14655.
21. Buttgereit, P., Schakowski, F., Marten, A., Brand, K., Renoth, S., Ziske, C., Schottker, B., Ebert, O., Schroers, R., Schmidt-Wolf, I.G., 2001. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther. 8, 430-439.
22. Campbell, S., Maxwell, A., 2002. The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by piggy-back binding. J. Mol. Biol. 320, 171-188.
23. Cardenas, M.E., Dang, Q., Glover, C., Gasser, S.M., 1992. Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vivo. EMBO J. 11, 1785-1796.
24. Cardoso, F., Di Leo, A., Larismont, D., Gancberg, D., Rouas, G., Dolci, S., Ferreira, F., Paesmans, M., Piccart, M., 2001. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann. Oncol. 12, 615-620.
25. Cascinu, S., Graziano, F., Del Ferro, E., Staccioli, M.P., Ligi, M., Carnevali, A., Muretto, P., Catalano, G., 1998. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83, 1917-1922.
26. Chang, B.-D., Swift, M.E., Shen, M., Fang, J., Broude, E.V., Roninson, I.B., 2002. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. U.S.A. 99, 389-394.
27. Chang, F.L., Lai, M.D., 2001. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J. Urol. 166, 304-310.
28. Coleman, L.W., Bronstein, I.B., Holden, J.A., 2001. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res. 21, 1167-1172.
29. Cowell, I.G., Okorokov, A.L., Cutts, S.A., Padget, K., Bell, M., Milner, J., Austin, C.A., 2000. Human topoisomerase IIα and IIβ interact with the C-terminal region of p53. Exp. Cell Res. 255, 86-94.
30. Damalas, A., Ben-Ze'ev, A., Simcha, I., Shtutman, M., Leal, J.F.M., Zhurinsky, J., Geiger, B., Oren, M., 1999. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18, 3054-3063.
31. Dan, S., Yamori, T., 2001. Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem. Biophys. Res. Commun. 280, 861-867.
32. de Belle, I., Cai, S., Kohwi-Shigematsu, T., 1998. The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J. Cell Biol. 141, 335-348.
33. De Vries, A., Flores, E.R., Miranda, B., Hsieh, H.-M., van Oostrom, C.T.M., Sage, J., Jacks, T., 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. U.S.A. 99, 2948-2953.
34. Dingemans, A.-M.C., Witlox, M.A., Stallaert, R.A.L.M., van der Valk, P., Postmus, P.E., Giaccone, G., 1999. Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res. 5, 2048-2058.
35. Drake, F.H., Zimmerman, J.P., McCabe, F.L., Bartus, H.F., Per, S.R., Sullivan, D.M., Ross, W.E., Mattern, M.R., Johnson, R.K., Crooke, S.T., Mirabelli, C.K., 1987. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262, 16739-16747.
36. Dubrez, L., Coll, J.-L., Hurbin, A., Solary, E., Favrot, M.-C., 2001. Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. J. Biol. Chem. 276, 38980-38987.
37. Dudenhoffer, C., Rohaly, G., Will, K., Deppert, W., Weismuller, L., 1998. Specific mismatch recognition in heteroduplex intermediates suggests a role in fidelity control of homologous recombination. Mol. Cell. Biol. 18, 5332-5342.
38. Elmore, L.W., Rehder, C.W., Di, X., McChesney, P.A., Jackson-Cook, C.K., Gewirtz, D.A., Holt, S.E., 2002. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 277, 35509-35515.
39. Fedier, A., Ruefenacht, U.B., Schwartz, V.A., Haller, U., Fink, D., 2002. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of pms2. Br. J. Cancer 87, 1027-1033.
40. Felix, C.A., 1998. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 233-255.
41. Fojo, T., 2002. P53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Updates 5, 209-216.
42. Foster, B.A., Coffey, H.A., Morin, M.J., Rastinejad, F., 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510.
43. Gangopadhyay, S., Jalali, F., Reda, D., Peacock, J., Bristow, R.G., Benchimol, S., 2002. Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents. Exp. Cell Res. 275, 122-131.
44. Gobert, C., Skladanowski, A., Larsen, A.K., 1999. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc. Natl. Acad. Sci. U.S.A. 96, 10355-10360.
45. Gohler, T., Reimann, M., Cherny, D., Walter, K., Warnecke, G., Kim, E., Deppert, W., 2002. Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain. J. Biol. Chem. 277, 41192-41203.
46. Gu, J., Nie, L., Wiederschain, D., Yuan, Z.-M., 2001. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol. Cell. Biol. 21, 8533-8546.
47. Gupta, D., Shidham, V., Holden, J., Layfield, L., 2001. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl. Immunohistochem. Mol. Morphol. 3, 215-221.
48. Hamilton, A., Larsimont, D., Paridaens, R., Drijkoningen, M., van de Vijver, M., Bruning, P., Hanby, A., Houston, S., Treilleux, I., Guastalla, J.P., Van Vreckem, A., Sylvester, R., Piccart, M., 2000. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin. Breast Cancer 1, 233-240.
49. Hauser, U., Balz, V., Carey, T.E., Grenman, R., van Lierop, A., Scheckenbach, K., Bier, H., 2002. Reliable detection of p53 aberations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24, 868-873.
50. Heck, M.M., Earnshaw, W.C., 1986. Topoisomerase II: a specific marker for cell proliferation. J. Cell Biol. 103, 2569-2581.
51. Heck, M.M., Hittelman, W.N., Earnshaw, W., 1989. In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. Cell cycle analysis. J. Biol. Chem. 264, 15161-15164.
52. Heck, M.M., Hittelman, W.N., Earnshaw, W.C., 1988. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. U.S.A. 85, 1086-1090.
53. Hochhauser, D., Stanway, C.A., Harris, A.L., Hickson, I.D., 1992. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J. Biol. Chem. 267, 18961-18965.
54. Hochhauser, D., Valkov, N.I., Gump, J.L., Wei, I., O'Hare, C., Hartley, J., Fan, J., Bertino, J.R., Banerjee, D., Sullivan, D.M., 1999. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines. J. Cell. Biochem. 75, 245-257.
55. Hosaka, N., Ichikawa, Y., Ishikawa, T., Nagashima, Y., Kunisaki, C., Takahashi, M., Moriwaki, Y., Akiyama, H., Yamaguchi, S., Ota, M., Ooki, S., Ike, H., Shimada, H., 2001. Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res. 21, 229-235.
56. Hu, Q., Bhattacharya, C., Maity, S.N., 2002. CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase IIα. Conventional CBF activation domains are not required. J. Biol. Chem. 277, 37191-37200.
57. Imanishi, R., Ohtsuru, A., Iwamatsu, M., Iioka, T., Namba, H., Seto, S., Yano, K., Yamashita, S., 2002. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab. 87, 4821-4824.
58. Inoue, A., Narumi, K., Matsubara, N., Sugawara, A.-i., Saijo, Y., Satoh, K., Nukiwa, T., 2000. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 157, 105-112.
59. Ito, A., Kawaguchi, Y., Lai, C.H., Kovacs, J.J., Higashimoto, Y., Appella, E., Yao, T.P., 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21, 6236-6245.
60. Jacob, S., Aguado, M., Fallik, D., Praz, F., 2001. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 61, 6555-6562.
61. Janus, F., Albrechtson, N., Dornreiter, I., Weismuller, L., Grosse, F., Deppert, W., 1999. The dual role model for p53 in maintaining genomic integrity. Cell. Mol. Life Sci. 55, 12-27.
62. Jarvinen, T.A., Holli, K., Kuukasjarvi, T., Isola, J.J., 1998. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer 77, 2267-2273.
63. Jia, L., Patwari, Y., Srinivasula, S.M., Newland, A.C., Fernandes-Alnemri, T., Alnemri, E.S., Kelsey, S.M., 2001. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 20, 4817-4826.
64. Jin, Y., Zeng, S.X., Dai, M.-S., Yang, X.-J., Lu, H., 2002. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 277, 30838-30843.
65. Joshi, A.A., Wang, Q., Suttle, D.P., 2000. p53 modulation of DNA topoisomerase II alpha gene expression. Cell Biochem. Biophys. 33, 209-216.
66. Juan, L.-J., Shia, W.-J., Chen, M.-H., Yang, W.-M., Seto, E., Lin, Y.-S., Wu, C.-W., 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275, 20436-20443.
67. Karpinich, N.O., Tafan, M., Rothman, R.J., Russo, M.A., Farber, J.L., 2002. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J. Biol. Chem. 277, 16547-16552.
68. Kaufmann, W.K., Campbell, C.B., Simpson, D.A., Deming, P.B., Filatov, L., Galloway, D.A., Zhao, X.J., Creighton, A.M., Downes, C.S., 2002. Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chromosomal destabilization. Cell Cycle 1, 210-219.
69. Kellner, U., Sehested, M., Jensen, P.B., Gieseler, F., Rudolph, P., 2002. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 3, 235-243.
70. Kemp, C.J., Sun, S., Gurley, K.E., 2001. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61, 327-332.
71. Keshelava, N., Zuo, J.J., Chen, P., Waidyaratne, S.N., Luna, M.C., Gomer, C.J., Triche, T.J., Reynolds, C.P., 2001. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185-6193.
72. Keshelava, N., Zuo, J.J., Waidyaratne, N.S., Triche, T.J., Reynolds, C.P., 2000. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med. Pediat. Oncol. 35, 563-568.
73. Kikuyama, S., Inada, T., Shimizu, K., Miyakita, M., Ogata, T., 2001. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res. 21, 2149-2153.
74. Kim, S.B., Ahn, I.M., Park, H.J., Park, J.S., Cho, H.J., Gong, G., Suh, C., Lee, J.S., Kim, W.K., Kim, S.H., 2001. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck 23, 223-229.
75. Kwon, Y., Shin, B.S., Chung, I.K., 2000. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIα by enhancing the rate of ATP hydrolysis. J. Biol. Chem. 275, 18503-18510.
76. Laurent, G., Jaffrezou, J.-P., 2001. Signaling pathways activated by daunorubicin. Blood 98, 913-924.
77. Lebedeva, S., Bagdasarova, S., Tyler, T., Mu, X., Wilson, D.R., Gjerset, R.A., 2001. Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53. Hum. Gene Ther. 12, 763-772.
78. Lee, D., Kim, J.W., Seo, T., Hwang, S.G., Choi, E.-J., Choe, J., 2002a. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem. 277, 22330-22337.
79. Lee, T.K., Lau, T.C., Ng, I.O., 2002b. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother. Pharmacol. 49, 78-86.
80. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R.D., Howell, S.B., 2001. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res. 61, 1508-1516.
81. Liu, D., Huang, C.L., Kameyama, K., Hayashi, E., Yamauchi, A., Sumimoto, S., Yokomise, H., 2002a. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in non-small cell lung carcinoma patients. Cancer 94, 2239-2247.
82. Liu, T., Raetz, E., Moos, P.J., Perkins, S.L., Bruggers, C.S., Smith, F., Carroll, W.L., 2002b. Diversity of the apoptotic response to chemotherapy in childhood leukemia. Leukemia 16, 223-232.
83. Liu, W.M., Oakley, P.R., Joel, S.P., 2002c. Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Leukemia 16, 1705-1712.
84. Lok, C.N., Lang, A.J., Mirski, S.E., Cole, S.P., 2002. Characterization of the human topoisomerase II beta (TOP2B) promoter activity: essential roles of the NF-Y and Sp1 binding sites. Biochem. J. 368, 741-751.
85. Luo, Y., Rockow-Magnone, S.K., Joseph, M.K., Bradner, J., Butler, C.C., Tahir, S.K., Han, E.K., Ng, S.C., Severin, J.M., Gubbins, E.J., Reilly, R.M., Rueter, A., Simmer, R.L., Holzman, T.F., Giranda, V.L., 2001. Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. Anticancer Res. 21, 23-28.
86. Lynch, B.J., Komaromy-Hiller, G., Bronstein, I.B., Holden, J.A., 1998. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum. Pathol. 29, 1240-1245.
87. Mahyar-Roemer, M., Roemer, K., 2001. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20, 3387-3398.
88. Mandziuk, S., Dudzisz-Sledz, M., Rybacka-Chabros, B., Zdunek, M., Jakubowicz-Klecha, A., Korobowicz, E., Milanowski, J., Wojcierowski, J., 2001. Expression of p21 and bcl-2 proteins and p53 mRNA in surgically resected preparations of non-small cell lung cancer (stage IIIA) after etoposide and cisplatin chemotherapy. Folia. Histochem. Cytobiol. 39 (Suppl. 2), 175-176.
89. Mao, Y., Desai, S.D., Ting, C.-Y., Hwang, J., Liu, L.F., 2001. 26S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 276, 40652-40658.
90. Mao, Y., Okada, S., Chang, L.-S., Muller, M.T., 2000. p53 dependence of topoisomerase I recruitment in vivo. Cancer Res. 60, 4538-4543.
91. Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., Rotter, V., 2001. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 20, 4163-4172.
92. Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K., Donner, D.B., 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484-5489.
93. McKenzie, P.P., McPake, C.R., Ashford, A.A., Vanin, E.F., Harris, L.C., 2002. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs. Mol. Cancer Ther. 1, 1097-1104.
94. McKinney, K., Prives, C., 2002. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22, 6798-6808.
95. Melixetian, M.B., Beryozkina, E., Pavlenko, M.A., Grinchuk, T.M., 2000. Altered expression of DNA-topoisomerase IIα is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells. Leuk. Res. 24, 831-837.
96. Mirski, S.E., Gerlach, J.H., Cummings, H.J., Zirngibl, R., Greer, P.A., Cole, S.P., 1997. Bipartite nuclear localization signals in the C-terminus of human topoisomerase II alpha. Exp. Cell Res. 237, 452-455.
97. Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., Wen, S.F., Wang, L., Kirschmeier, P., Bishop, W.R., Nielsen, L.L., Pickett, C.B., Liu, S., 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21, 2613-2622.
98. Miyaki, M., Iijima, T., Yasuno, M., Kita, Y., Hishima, T., Kuroki, T., Mori, T., 2002. High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas. Oncogene 21, 6689-6693.
99. Monnin, K.A., Bronstein, I.B., Gaffney, D.K., Holden, J.A., 1999. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum. Pathol. 30, 384-391.
100. Morris, S.M., 2002. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 511, 45-62.
101. Mottolese, M., Benevelo, M., Del Monte, G., Buglioni, S., Papaldo, P., Nistico, C., Di Filippo, F., Vasselli, S., Vici, P., Botti, C., 2000. Role of p53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J. Cancer Res. Clin. Oncol. 126, 722-729.
102. Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., Grosse, F., 1996. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell 85, 1089-1099.
103. Nakamura, S., Gomyo, Y., Roth, J.A., Mukhopadhyay, T., 2002. C-terminus of p53 is required for G(2) arrest. Oncogene 21, 2102-2107.
104. Nakopoulou, L., Lazaris, A.C., Kavantzas, N., Alexandrou, P., Athanassiadou, P., Keramopoulos, A., Davaris, P., 2000. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68, 137-143.
105. Nayak, B.K., Das, G.M., 2002. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene 21, 7226-7229.
106. Nemunaitis, J., Cunningham, C., 2002. Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist. Updates 5, 34-46.
107. Nemunaitis, J., Senzer, N., Cunningham, C., Dubensky, T.W., 2001. Virus-mediated killing of cells that lack p53 activity. Drug Resist. Updates 4, 289-291.
108. Nip, J., Hiebert, S.W., 2000. Topoisomerase II alpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression. Cell Biochem. Biophys. 33, 199-207.
109. O'Connor, P.M., Jackman, J., Bae, I., Myers, T.G., Fan, S., Mutoh, M., Scudiero, D.A., Monks, A., Sausville, E.A., Weinstein, J.N., Friend, S., Fornace, Jr., A.J., Kohn, K.W., 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300.
110. Ogiso, Y., Tomida, A., Tsuruo, T., 2002. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumors cells to topoisomerase II-directed drugs. Cancer Res. 62, 5008-5012.
111. Okorokov, A.L., Milner, J., 1997. Proteolytic cleavage of p53: a model for the activation of p53 in response to DNA damage. Oncology Res. 9, 267-273.
112. Okorokov, A.L., Ponchel, F., Milner, J., 1997. Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J. 16, 6008-6017.
113. Osugi, H., Morimura, K., Okuda, E., Takemura, M., Higashino, M., Takada, N., Kinoshita, H., 2002. p53 null mutations detected by a p53 yeast functional assay predict a poor outcome in young esophageal carcinoma patients. Int. J. Oncol. 21, 637-641.
114. Reddy, G., Khanna, N., Singh, N., 2001. Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing p53. Biochem. Biophys. Res. Commun. 282, 409-415.
115. Rein, D.T., Schondorf, T., Breidenbach, M., Janat, M.M., Weikelt, A., Gohring, U.J., Becker, M., Mallmann, P., Kurbacher, C.M., 2000. Lack of correlation between p53 expression, BCL-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer. Anticancer Res. 20, 5069-5072.
116. Rodriguez-Lopez, A., Xenaki, D., Eden, T.O.B., Hickman, J.A., Chresta, C.M., 2000. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol. Pharmacol. 59, 135-143.
117. Roninson, I.B., 2002. Tumor senescence as a determinant of drug response in vivo. Drug Resist. Updates 5, 204-208.
118. Roninson, I.B., Broude, E.V., Chang, B.-D., 2001. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updates 4, 303-313.
119. Rosson, G.B., Vincent, T.S., Oswald, B.W., Wright, C.F., 2002. Drug resistance in malignant rhabdoid tumor cell lines. Cancer Chemother. Pharmacol. 49, 142-148.
120. Sabbatini, P., McCormick, F., 2002. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 21, 519-525.
121. Saintigny, Y., Dumay, S., Lambert, S., Lopez, B.S., 2001. A novel role for the bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 20, 2596-2607.
122. Sakaguchi, A., Miyaike, M., Kuroda, K., Nozaki, N., Tanaka, M., Hibino, M., Fujii, Y., Kato, S., Kikuchi, A., 2002. Epitope distribution of randomly established monoclonal antibodies against human type II DNA topoisomerases. J. Biochem. 132, 409-416.
123. Salmena, L., Lam, V., McPherson, J.P., Goldenberg, G.J., 2001. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIα expression. Biochem. Pharmacol. 61, 795-802.
124. Sasaki, Y., Morimoto, I., Ishida, S., Yamashita, T., Imai, K., Tokino, T., 2001. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer. Gene Ther. 8, 1401-1408.
125. Sax, J.K., Fei, P., Murphy, M.E., Bernhard, E., Korsmeyer, S.J., El-Deiry, W.S., 2002. BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 4, 842-849.
126. Schmitt, C.A., Lowe, S.W., 2001. Apoptosis is critical for drug response in vivo. Drug Resist. Updates 4, 132-134.
127. Scovassi, A.L., Pellegata, N.S., Di Stefano, L., Padovan, L., Negri, C., Prosperi, E., Riva, F., Ciomei, M., Ranzani, G.N., 2001. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions. Anticancer Res. 21, 2803-2808.
128. Shah, N.L., Kielb, S.J., Sanda, M.G., 2002. The effect of functional and mutant p53 on M-VAC therapy in human bladder cancer: implications for molecular targeting of neoadjuvant chemotherapy. Proc. AACR Abstr.# 1257.
129. Shao, J., Teraishi, F., Katsuda, K., Tanaka, N., Fujiwara, T., 2002. p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells. Biochem. Biophys. Res. Commun. 290, 1101-1107.
130. Sharp, J.G., Bishop, M.R., Copple, B., Greiner, T.C., Iversen, P.L., Jackson, J.D., Joshi, S.S., Benner, E.J., Mann, S.L., Rao, A.K., Vose, J.M., 2001. Oligonucleotide enhanced cytotoxicity of idarubicin for lymphoma cells. Leuk. Lymphoma 42, 417-427.
131. Shimada, H., Okazumi, S., Takeda, A., Nabeya, Y., Matsubara, H., Funami, Y., Ha yashi, H., Gunji, Y., Suzuki, T., Ochiai, T., 2001. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg. Today 31, 591-596.
132. Shirakawa, T., Sasaki, R., Gardiner, T.A., Kao, C., Zhang, Z.-J., Sugumura, K., Matsua, M., Kamidono, S., Gotoh, A., 2001. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells. Int. J. Cancer 94, 282-289.
133. Sidi, Y., Lilling, G., Kovalski, V., Bakhanashvili, M., 2002. Cytoplasmic wt p53 is functional. Proc. AACR Abstr.# 5659.
134. Simoes-Wust, A.P., Schurpf, T., Hall, J., Stahel, R.A., Zangemeister-Wittke, U., 2002. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76, 157-166.
135. Skalsky, V., Lin, Z.-Y., Choi, B.Y., Brown, K.R., 2000. Substrate specificity of the p53-associated 3′-5′ exonuclease. Oncogene 19, 3321-3329.
136. Song, S.U., Boyce, F.M., 2001. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp. Mol. Med. 33, 46-53.
137. Soues, S., Wiltshire, M., Smith, P.J., 2001. Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction. Cancer Chemother. Pharmacol. 47, 133-140.
138. Stommel, J.M., Marchenko, N.D., Jimenez, G.S., Moll, U.M., Hope, T.J., Wahl, G.M., 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672.
139. Takimoto, R., Wang, W., Dicker, D.T., Rastinejad, F., Lyssikatos, J., el-Deiry, W.S., 2002. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1, 47-55.
140. Tarapore, P., Fukasawa, K., 2002. Loss of p53 and centrosome hyperamplification. Oncogene 21, 6234-6240.
141. Tsai-Pflugfelder, M., Liu, L.F., Liu, A.A., Tewey, K.M., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C.M., Wang, J.C., 1988. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. U.S.A. 85, 7177-7181.
142. Vogt, P., Zaczek, A., Klinke, F., Granetzny, A., Bielawski, K., Falkiewicz, B., 2002. p53 gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 128, 141-147.
143. Wang, L., Eastmond, D.A., 2002. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187. Environ. Mol. Mutagen. 39, 348-356.
144. Wang, Q., Zambetti, G.P., Suttle, D.P., 1997. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol. Cell. Biol. 17, 389-397.
145. Watanuki, A., Ohwada, S., Fukusato, T., Makita, F., Yamada, T., Kikuchi, A., Morishita, Y., 2002. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res. 22, 1113-1119.
146. Wu, G.S., Ding, Z., 2002. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21, 1-8.
147. Wu, Z., Suttle, D.P., 2002. Topoisomerase II-dependent cell cycle G2/M arrest is distinct from DNA damage arrest. Proc. AACR Abstr.# 3104.
148. Yang, H.L., Dong, Y.B., Elliott, M.J., Wong, S.L., McMasters, K.M., 2001. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells. Cancer Gene Ther. 8, 241-251.
149. Yin, D., Tamaki, N., Kokunai, T., 2000. Wild-type p53-dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells. J. Neurosurg. 93, 289-297.
150. Zechiedrich, E.L., Osheroff, N., 1990. Eukaryotic topoisomerases recognize nuclei acid topology by preferentially interacting with DNA crossovers. EMBO J. 9, 4555-4562.
151. Zhan, M., Yu, D., Lang, A., Li, L., Pollock, R.E., 2001. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 92, 1556-1566.
152. Zhou, M., Gu, L., Li, F., Zhu, Y., Woods, W.G., Findley, H.W., 2002. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Therap. 303, 124-131.
153. Zhu, C., Mills, K.D., Ferguson, D.O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C.C., Alt, F.W., 2002a. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic, gene amplification subsequent to translocations. Cell 109, 811-821.
154. Zhu, H., Chang, B.D., Uchiumi, T., Roninson, I.B., 2002b. Identification of promoter elements responsible for transcriptional inhibition of Polo-like Kinase 1 and topoisomerase IIalpha genes by p21 (WAF1/CIP1/SDI1). Cell Cycle 1, 59-66.